Managing Adult Refractory Epilepsy Patients: Why it is important to consider genetic epilepsy syndromes

Released On
October 16, 2020

Expires On
October 16, 2021

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.

This activity is supported by an educational grant from Zogenix, Inc.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The educational design of this activity addresses the needs of pediatric and adult neurologists, epileptologists, pediatricians, pharmacists, and aligned specialists (RNs, NPs, PAs). involved in the treatment of patients with epilepsy.

Statement of Need/Program Overview

Due to early mortality rates, Dravet syndrome is often considered a pediatric-only condition; in fact, about 80% of these patients will survive into adulthood and require lifelong care. In addition, a recent survey found that one-third of patients with Dravet syndrome were not correctly diagnosed until adulthood. Clinicians must have a higher index of suspicion for Dravet syndrome in their adult patients and recognize when to reconsider diagnoses in those with drug-resistant epilepsy. An improved understanding of the genetic underpinnings of Dravet syndrome has been instrumental in guiding diagnosis and treatment selection in children and may open doors for adult patients with intractable epilepsy moving forward.

Join us for this important educational activity, as Dr. M. Scott Perry and Dr. Danielle M. Andrade review the optimal care of adults with refractory epilepsy, along with key concepts related to Dravet syndrome. Learn when to consider genetic testing to help guide a precision-medicine approach, when to refer for a specialist evaluation, and how new treatments are providing renewed hope to some adult patients with intractable epilepsy.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the disease burden experienced by adults with drug-resistant epilepsy and their caregivers
  • Explain the impact of incorrect diagnosis on treatment responseTWO
  • Define how new diagnostic approaches (including genetic testing) and management options have the potential to improve the outcomes of patients with developmental and epileptic encephalopathies (DEEs) such as Dravet syndromeTHREE
  • Discuss the implications of recent developments in the management of various DEEs in pediatric and adolescent patients and its potential impact on treating adults with refractory epilepsy


M. Scott Perry, MD

Medical Director, Neurology
Co-Director, Jane and John Justin Neurosciences Center
Director, Genetic Epilepsy Clinic
Cook Children’s Medical Center
Fort Worth, TX

Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

Professor of Medicine (Neurology)
Medical Director, Epilepsy Program
Director of Epilepsy Genetics Research Program
Director, Epilepsy Transition Program
University of Toronto

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

M. Scott Perry, MD

  • Consultant/Independent Contractor: Stoke: advisory board/consultant; Encoded: consultant/advisory board
  • Grant/Research Support: Research support paid to Cook Children's from Stoke, Greenwich, Zogenix, Marinus, Ovid
  • Speaker’s Bureau: Biocodex: speakers bureau
  • Advisory Board: Zogenix: advisory board; Greenwich Biosciences: advisoryboard; Stoke: advisory board; Encoded: advisory board

Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

  • Honoraria: UCB
  • Advisory Board: Stroke Therapeutics
  • Royalty: UpToDate

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky has no financial relationships to disclose.

Andrea Funk has no financial relationships to disclose.

Liddy Knight has no financial relationships to disclose.

Ashley Cann has no financial relationships to disclose.

Carole Drexel has no financial relationships to disclose.

Elizabeth del Nido has no financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: